Tranexamic Acid for Acute Spontaneous Intracerebral Hemorrhage: A Meta-Analysis of Randomized Controlled Trials

Yu Guo; Xin-Mei Guo; Rui-Li Li; Kai Zhao; Qiang-Ji Bao; Jin-Cai Yang; Qiang Zhang; Ming-Fei Yang

doi:10.3389/fneur.2021.761185

Tranexamic Acid for Acute Spontaneous Intracerebral Hemorrhage: A Meta-Analysis of Randomized Controlled Trials

Front Neurol. 2021 Dec 20:12:761185. doi: 10.3389/fneur.2021.761185. eCollection 2021.

Authors

Yu Guo¹, Xin-Mei Guo², Rui-Li Li³, Kai Zhao¹, Qiang-Ji Bao¹, Jin-Cai Yang¹, Qiang Zhang⁴, Ming-Fei Yang⁴

Affiliations

¹ Graduate School, Qinghai University, Xining, China.
² Biomedical Engineering Research Center, Kunming Medical University, Kunming, China.
³ Neurological Intensive Care Department, Shengli Oilfield Central Hospital, Dongying, China.
⁴ Department of Neurosurgery, Qinghai Provincial People's Hospital, Xining, China.

Abstract

Background: The role of tranexamic acid (TXA) in preventing hematoma expansion (HE) in patients with acute spontaneous intracerebral hemorrhage (ICH) remains unclear. We aim to investigate the efficacy and safety of TXA in acute spontaneous ICH with a particular focus on subgroups. Methods: Randomized controlled trials (RCTs) were retrieved from CENTRAL, Clinicaltrials.gov, EMBASE, PubMed, and WHO ICTRP. The primary outcome measurement was HE. The secondary outcome measurements included 3-month poor functional outcome (PFO), 3-month mortality, and major thromboembolic events (MTE). We conducted subgroup analysis according to the CT markers of HE (standard-risk population and high-risk population) and the time from onset to randomization (>4.5 and ≤4.5 h). Results: We identified seven studies (representing five RCTs) involving 2,650 participants. Compared with placebo, TXA may reduce HE on subsequent imaging (odd ratio [OR] 0.825; 95% confidence interval [CI] 0.692-0.984; p = 0.033; I² = 0%; GRADE: moderate certainty). TXA and placebo arms did not differ in the rates of 3-month PFO, 3-month mortality, and MTE. Subgroup analysis indicated that TXA reduced the risk of HE in the high-risk population with CT markers of HE (OR 0.646; 95% CI 0.503-0.829; p = 0.001; I² = 0 %) and in patients who were treated within 4.5 h of symptom onset (OR 0.823; 95% CI 0.690-0.980; p = 0.029; I² = 0%), but this protective effect was not observed in the standard-risk population and patients who were treated over 4.5 h of symptom onset. Conclusions: Tranexamic acid (TXA) may decrease the risk of HE in patients with acute spontaneous ICH. Importantly, the decreased risk was observed in patients who were treatable within 4.5 h and with a high risk of HE, but not in those who were treatable over 4.5 h and in standard-risk population. However, PFO or mortality at 3 months did not significantly differ between patients who received TXA and those who received placebo. TXA is safe for acute spontaneous ICH without increasing MTE.

Keywords: cerebral hemorrhage; hematoma; meta-analysis; randomized controlled trial; tranexamic acid.

Publication types

Systematic Review